Article
Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.
PloS one - 1 Jan 2018
Morris Scott M, Subramanian Janakiraman, Gel Esma S, Runger George C, Thompson Eric J, Mallery David W, Weiss Glen J
Abstract excerpt
BACKGROUND: Next generation sequencing tests (NGS) are usually performed on relatively small core biopsy or fine needle aspiration (FNA) samples. Data is limited on what amount of tumor by volume or minimum number of FNA passes are needed to yield sufficient material for running NGS. We sought to identify the amount of tumor for running the PCDx NGS platform. METHODS: 2,723 consecutive tumor tissues of all cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.